CME/CE Podcast: VMAT2 Inhibitors in TD: Similarities & Differences

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/vmat2-inhibitors-in-tardive-dyskinesia-9799

Summary
Tardive dyskinesia (TD) is a syndrome characterized by various iatrogenic movement disorders resulting from dopamine receptor antagonism. These movement disorders include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other abnormal involuntary movements, most commonly emerging after prolonged antipsychotic use.

Vesicular monoamine transporter type 2 (VMAT2) inhibitors are now available in the United States for managing dyskinesia syndromes, each with a slightly different range of approved indications. VMAT2 inhibitors are agents that cause a depletion of neuroactive peptides such as dopamine in nerve terminals and are used to treat chorea due to neurodegenerative diseases or dyskinesias due to neuroleptic medications (tardive dyskinesia).

In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the structural and pharmacokinetic differences between these agents, understanding how they modulate dopamine levels at hypersensitive D2 receptors, common in TD. The program emphasizes the importance of VMAT2 inhibition and its interaction with antipsychotic medications.

This podcast was recorded and is being used with permission of the presenters.

Learning Objective
At the conclusion of this activity, participants should be better able to:

• Examine the pharmacologic differences between the various VMAT2 inhibitors

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from Neurocrine Biosciences.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.